KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.
The BOOST trial - led by researchers at the University of Plymouth and experts across the UK - will assess whether the Β-hydroxy β-methylbutyrate (HMB) supplement can benefit some of the 60,000 people ...